Galapagos had strong cash position at end of first half

Galapagos NV reported cash and cash equivalents of €1.3 billion on 30 June in a first-half year report that also highlighted an ambitious research and development programme for small molecules targeting inflammatory indications and cystic fibrosis.

Full text available to subscribers only. Click here for information on subscribing to MedNous.